Synonyms: CNP-520 | CNP520 | compound 15 [PMID: 34648711]
Compound class:
Synthetic organic
Comment: Umibecestat (CNP520) was an investigational β-secretase (BACE1) inhibitor [2]. It was designed for potential to slow the onset of clinical symptoms caused by Alzheimer's disease [1,3].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Dobrowolska Zakaria JA, Vassar RJ. (2018)
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease. EMBO Mol Med, 10 (11): e9717. [PMID:30322841] |
2. Machauer R, Lueoend R, Hurth K, Veenstra SJ, Rueeger H, Voegtle M, Tintelnot-Blomley M, Rondeau JM, Jacobson LH, Laue G et al.. (2021)
Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease. J Med Chem, 64 (20): 15262-15279. [PMID:34648711] |
3. Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K et al.. (2018)
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO Mol Med, 10 (11): e9316. [PMID:30224383] |